Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.25
NVSEF's Cash to Debt is ranked lower than
83% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. NVSEF: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
NVSEF' s 10-Year Cash to Debt Range
Min: 0.2  Med: 1.23 Max: N/A
Current: 0.25
Equity to Asset 0.58
NVSEF's Equity to Asset is ranked lower than
57% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NVSEF: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
NVSEF' s 10-Year Equity to Asset Range
Min: 0.51  Med: 0.59 Max: 0.65
Current: 0.58
0.51
0.65
Interest Coverage 15.75
NVSEF's Interest Coverage is ranked lower than
77% of the 389 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2854.00 vs. NVSEF: 15.75 )
Ranked among companies with meaningful Interest Coverage only.
NVSEF' s 10-Year Interest Coverage Range
Min: 13.56  Med: 18.99 Max: 30.91
Current: 15.75
13.56
30.91
F-Score: 6
Z-Score: 3.21
M-Score: -2.26
WACC vs ROIC
8.57%
10.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 19.64
NVSEF's Operating margin (%) is ranked higher than
81% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.78 vs. NVSEF: 19.64 )
Ranked among companies with meaningful Operating margin (%) only.
NVSEF' s 10-Year Operating margin (%) Range
Min: 17.81  Med: 21.87 Max: 24.34
Current: 19.64
17.81
24.34
Net-margin (%) 38.27
NVSEF's Net-margin (%) is ranked higher than
96% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. NVSEF: 38.27 )
Ranked among companies with meaningful Net-margin (%) only.
NVSEF' s 10-Year Net-margin (%) Range
Min: 15.35  Med: 19.24 Max: 31.38
Current: 38.27
15.35
31.38
ROE (%) 27.26
NVSEF's ROE (%) is ranked higher than
88% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. NVSEF: 27.26 )
Ranked among companies with meaningful ROE (%) only.
NVSEF' s 10-Year ROE (%) Range
Min: 12.6  Med: 16.53 Max: 25.73
Current: 27.26
12.6
25.73
ROA (%) 15.49
NVSEF's ROA (%) is ranked higher than
86% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.32 vs. NVSEF: 15.49 )
Ranked among companies with meaningful ROA (%) only.
NVSEF' s 10-Year ROA (%) Range
Min: 7.21  Med: 10.35 Max: 16.18
Current: 15.49
7.21
16.18
ROC (Joel Greenblatt) (%) 61.84
NVSEF's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.13 vs. NVSEF: 61.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVSEF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 43.77  Med: 64.13 Max: 90.24
Current: 61.84
43.77
90.24
Revenue Growth (3Y)(%) -2.10
NVSEF's Revenue Growth (3Y)(%) is ranked lower than
74% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NVSEF: -2.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVSEF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.9  Med: 4.80 Max: 73.5
Current: -2.1
-3.9
73.5
EBITDA Growth (3Y)(%) 5.40
NVSEF's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 492 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. NVSEF: 5.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVSEF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7  Med: 1.95 Max: 82.8
Current: 5.4
-7
82.8
EPS Growth (3Y)(%) 6.00
NVSEF's EPS Growth (3Y)(%) is ranked higher than
51% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVSEF: 6.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVSEF' s 10-Year EPS Growth (3Y)(%) Range
Min: -7.2  Med: 4.75 Max: 82.3
Current: 6
-7.2
82.3
» NVSEF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 12.53
NVSEF's P/E(ttm) is ranked higher than
88% of the 479 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.40 vs. NVSEF: 12.53 )
Ranked among companies with meaningful P/E(ttm) only.
NVSEF' s 10-Year P/E(ttm) Range
Min: 7.87  Med: 16.77 Max: 25.64
Current: 12.53
7.87
25.64
Forward P/E 18.05
NVSEF's Forward P/E is ranked higher than
64% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. NVSEF: 18.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.60
NVSEF's PE(NRI) is ranked higher than
64% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.40 vs. NVSEF: 24.60 )
Ranked among companies with meaningful PE(NRI) only.
NVSEF' s 10-Year PE(NRI) Range
Min: 10.63  Med: 17.96 Max: 26.72
Current: 24.6
10.63
26.72
P/B 3.19
NVSEF's P/B is ranked higher than
50% of the 644 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.12 vs. NVSEF: 3.19 )
Ranked among companies with meaningful P/B only.
NVSEF' s 10-Year P/B Range
Min: 1.69  Med: 2.54 Max: 4.14
Current: 3.19
1.69
4.14
P/S 4.62
NVSEF's P/S is ranked lower than
62% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.13 vs. NVSEF: 4.62 )
Ranked among companies with meaningful P/S only.
NVSEF' s 10-Year P/S Range
Min: 1.89  Med: 3.15 Max: 5
Current: 4.62
1.89
5
PFCF 24.01
NVSEF's PFCF is ranked higher than
75% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.27 vs. NVSEF: 24.01 )
Ranked among companies with meaningful PFCF only.
NVSEF' s 10-Year PFCF Range
Min: 7.03  Med: 17.37 Max: 26.64
Current: 24.01
7.03
26.64
POCF 17.82
NVSEF's POCF is ranked higher than
72% of the 387 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.20 vs. NVSEF: 17.82 )
Ranked among companies with meaningful POCF only.
NVSEF' s 10-Year POCF Range
Min: 5.75  Med: 13.23 Max: 19.28
Current: 17.82
5.75
19.28
EV-to-EBIT 22.10
NVSEF's EV-to-EBIT is ranked higher than
56% of the 488 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.19 vs. NVSEF: 22.10 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s 10-Year EV-to-EBIT Range
Min: 8.9  Med: 16.30 Max: 27.3
Current: 22.1
8.9
27.3
Shiller P/E 20.98
NVSEF's Shiller P/E is ranked higher than
73% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.90 vs. NVSEF: 20.98 )
Ranked among companies with meaningful Shiller P/E only.
NVSEF' s 10-Year Shiller P/E Range
Min: 9.22  Med: 14.72 Max: 24.94
Current: 20.98
9.22
24.94
Current Ratio 0.84
NVSEF's Current Ratio is ranked lower than
93% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. NVSEF: 0.84 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s 10-Year Current Ratio Range
Min: 0.84  Med: 1.41 Max: 2.83
Current: 0.84
0.84
2.83
Quick Ratio 0.62
NVSEF's Quick Ratio is ranked lower than
90% of the 617 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. NVSEF: 0.62 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s 10-Year Quick Ratio Range
Min: 0.62  Med: 1.16 Max: 2.48
Current: 0.62
0.62
2.48
Days Inventory 134.76
NVSEF's Days Inventory is ranked lower than
61% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.66 vs. NVSEF: 134.76 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s 10-Year Days Inventory Range
Min: 117.85  Med: 174.33 Max: 297.22
Current: 134.76
117.85
297.22
Days Sales Outstanding 60.19
NVSEF's Days Sales Outstanding is ranked higher than
60% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.39 vs. NVSEF: 60.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s 10-Year Days Sales Outstanding Range
Min: 53.85  Med: 64.06 Max: 79.16
Current: 60.19
53.85
79.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.73
NVSEF's Dividend Yield is ranked higher than
90% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. NVSEF: 2.73 )
Ranked among companies with meaningful Dividend Yield only.
NVSEF' s 10-Year Dividend Yield Range
Min: 1.47  Med: 3.05 Max: 5.11
Current: 2.73
1.47
5.11
Dividend Payout 0.68
NVSEF's Dividend Payout is ranked higher than
79% of the 396 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NVSEF: 0.68 )
Ranked among companies with meaningful Dividend Payout only.
NVSEF' s 10-Year Dividend Payout Range
Min: 0.51  Med: 1.53 Max: 2.73
Current: 0.68
0.51
2.73
Dividend growth (3y) 6.80
NVSEF's Dividend growth (3y) is ranked higher than
50% of the 255 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NVSEF: 6.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
NVSEF' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 7.45 Max: 18.5
Current: 6.8
0
18.5
Yield on cost (5-Year) 3.97
NVSEF's Yield on cost (5-Year) is ranked higher than
93% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. NVSEF: 3.97 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVSEF' s 10-Year Yield on cost (5-Year) Range
Min: 2.14  Med: 4.44 Max: 7.44
Current: 3.97
2.14
7.44
Share Buyback Rate -0.20
NVSEF's Share Buyback Rate is ranked higher than
74% of the 459 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. NVSEF: -0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
NVSEF' s 10-Year Share Buyback Rate Range
Min: 41.9  Med: 0.90 Max: -2.5
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 21.66
NVSEF's Price/Tangible Book is ranked lower than
94% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. NVSEF: 21.66 )
Ranked among companies with meaningful Price/Tangible Book only.
NVSEF' s 10-Year Price/Tangible Book Range
Min: 0.16  Med: 4.09 Max: 94.26
Current: 21.66
0.16
94.26
Price/Projected FCF 1.50
NVSEF's Price/Projected FCF is ranked higher than
73% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. NVSEF: 1.50 )
Ranked among companies with meaningful Price/Projected FCF only.
NVSEF' s 10-Year Price/Projected FCF Range
Min: 0.67  Med: 1.04 Max: 1.89
Current: 1.5
0.67
1.89
Price/Median PS Value 1.51
NVSEF's Price/Median PS Value is ranked lower than
60% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.28 vs. NVSEF: 1.51 )
Ranked among companies with meaningful Price/Median PS Value only.
NVSEF' s 10-Year Price/Median PS Value Range
Min: 0.66  Med: 1.17 Max: 3.21
Current: 1.51
0.66
3.21
Price/Graham Number 4.92
NVSEF's Price/Graham Number is ranked lower than
81% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.43 vs. NVSEF: 4.92 )
Ranked among companies with meaningful Price/Graham Number only.
NVSEF' s 10-Year Price/Graham Number Range
Min: 0.07  Med: 1.87 Max: 76.65
Current: 4.92
0.07
76.65
Earnings Yield (Greenblatt) (%) 4.55
NVSEF's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. NVSEF: 4.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVSEF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.7  Med: 6.10 Max: 11.3
Current: 4.55
3.7
11.3
Forward Rate of Return (Yacktman) (%) 2.08
NVSEF's Forward Rate of Return (Yacktman) (%) is ranked lower than
62% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.18 vs. NVSEF: 2.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVSEF' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.5  Med: 14.30 Max: 79.4
Current: 2.08
0.5
79.4

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 52,187 52,534 56,350
EPS($) 5.08 5.34 6.21
EPS without NRI($) 5.08 5.34 6.21

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NVS.USA, NOT.Germany, NOTA.Germany, NVS.Argentina, NVS N.Mexico, NOVNEE.Switzerland,
Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includes innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and they report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVSEF

Headlines

Articles On GuruFocus.com
[email protected] Aug 26 2015 
[email protected] Aug 26 2015 
Valeant Pharmaceuticals' New Female Drug Aug 20 2015 
Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
Bill Frels' Stocks With Growing Yields Jun 27 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
Billionaire George Soros Ups Two Stakes in First Quarter Jun 16 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 

More From Other Websites
Novartis' (NVS) Promacta Label Further Expanded in U.S. Aug 26 2015
FDA Grants Expanded Use of Promacta for Novartis Aug 24 2015
Novartis could pay more than $1B for GlaxoSmithKline MS drug Aug 21 2015
GSK sells cancer and multiple sclerosis drug to Novartis in $1bn deal Aug 21 2015
Novartis buys remaining rights to GSK treatment for up to $1 bln Aug 21 2015
Novartis to Acquire Rights to Glaxo MS Drug for Up to $1 Billion Aug 21 2015
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data Aug 19 2015
Wait, There are Still Cheap Pharma Stocks? Aug 18 2015
​Aveo, the Cambridge biotech that refuses to die, sees stock jump after $326M deal Aug 17 2015
Is AVEO the Next Aquinox for Traders? Aug 17 2015
Why drug companies are betting big on ‘pharmerging’ countries Aug 14 2015
Is Pfizer Inc. Considering A £19-Per-Share Offer For GlaxoSmithKline plc? Aug 07 2015
Glaxo's Best ‘Headache' Remedy May Be Buying Stakes in Ventures Aug 06 2015
Will Biogen Win From Novartis MS Drug Safety Label Change? Aug 04 2015
5 Biotechs With Catalysts Coming This Week Aug 03 2015
GlaxoSmithKline (GSK) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog Jul 30 2015
Novartis’s Shares Fall after 2Q15 Earnings Jul 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK